Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439308 | 0.89 | KMT2A (1.00) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL2752715 | 0.83 | RAB9A (0.97) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL813710 | 0.81 | KMT2A (0.79) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL28651774 | 0.81 | KMT2A (0.79) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL11336178 | 0.81 | RAB9A (1.00) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL1514659 | 0.81 | EPHX1 (0.83) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL2751737 | 0.79 | KMT2A (0.76) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL2751208 | 0.79 | RAB9A (0.97) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL5950648 | 0.79 | NPC1 (0.78) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL10089305 | 0.79 | EPHX1 (1.00) | KMT2ASMN1; SMN2MEN1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | STARPHARMA LIMITED (AU) | 2002-09-12 | — | — | US | disclosed |
| WO-2002030886-A2 | HETEROCYCLIC ANGIOGENESIS INHIBITORS | MATTHEWS BARRY R (AU) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | KDR, CBR3, OGFR | KMT2A 3578/4885SMN1; SMN2 2828/4885MEN1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.